Exosome Diagnostics and Therapeutic Market: Greater Precision and Advantages over Traditional Methods of Diagnosis and Therapeutics

The exosome diagnostic and therapeutic market is expected to grow owing to factors such as greater precision and advantages over traditional methods of diagnosis and therapeutics and increasing number of research activities in the field of exosomes. However, poor infrastructure and lack of expertise required for isolation of exosomes are likely to restrain the growth of the market during the forecast period.

Leading companies operating in the exosome diagnostic and therapeutic market are Aethlon Medical, Inc., Therapeutic Solutions International, Inc., ReNeuron Group plc, Immune Therapy Holdings AB, Cell Guidance Systems LLC, BioRegenerative Sciences, Evomic Science LLC, NorgenBiotek Corp., Exosome Diagnostics, Inc./Bio-Techne, and MiltenyiBiotec, among others.

Request for sample PDF Copy @ https://www.theinsightpartners.com/sample/TIPRE00005514/?utm_source=OpenPR&utm_medium=10144

The exosome diagnostic and therapeutic market was valued at US$ 41.6.33 million in 2019 and is expected to grow at a CAGR of 32.2% from 2020 to 2027 to reach US$ 358.91 million 2027.

Exosomes are distinct populations of tiny membranous vesicles, released into the extracellular space by most cells, which get eventually accumulated in the body fluid circulation. By acting as cellular messengers, they play a role in vital physiological functions by transporting information between different cell types. These tiny particles carry cellular nucleic acids and proteins from their host cells to target cells, which represent the comprehensive information about pathophysiological conditions of the host cell. For instance, exosomes released from tumor cells contains tumor-specific RNAs that can be potentially detected during cancer diagnosis.

These carrier exosomes can also be used as biomarkers in the diagnosis of neurodegenerative and metabolic disorders, and infectious and other diseases. Additionally, the presence of exosomes in body fluids such as saliva and urine islikely to rule out the traditional methods involving the collection of the invasive body fluids.Thus, the growing emphasis on clinically noninvasive diagnosis is likely to drive the adoption of exosomes-based diagnosis and therapeutics in the medical industry during the forecast period.

The global exosome diagnostic and therapeutic market, based on application, is further segmented into diagnostic and therapeutic. The diagnostic segment held a larger share of the market in 2019. Also, the diagnostic segment is estimated to register a higher CAGR during the forecast period owing to increasing adoption to exosomes for the diagnosis of chronic conditions and increasing awareness of procedural outcomes served by exosomes. Increasing awareness about exosomes diagnostics is propelling the companies to enter into this market to tap lucrative opportunities. For instance, in March 2016, Sysmex and JVCKENWOOD launched a joint program for the development of diagnostic instruments for measurement of exosomes.

Place an order copy of this report @ https://www.theinsightpartners.com/buy/TIPRE00005514/?utm_source=OpenPR&utm_medium=10144

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876

This release was published on openPR.